Rufinamide efficacy and safety in children aged 1–4 years with Lennox–Gastaut syndrome

Shin Hye Kim, Hoon Chul Kang, Joon Soo Lee, Heung Dong Kim

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Purpose: The treatment options for Lennox–Gastaut syndrome (LGS), a pediatric epileptic syndrome, are limited, especially in younger children. Rufinamide tablets were safe and effective as an add-on treatment in Korean children and adolescents <20 years of age with LGS. This subgroup analysis aimed to evaluate the efficacy and safety of rufinamide tablets in LGS pediatric patients aged 1–4 years. Methods: This was a retrospective, observational study in LGS patients aged 1–4 years who received 12 weeks of treatment with rufinamide orally as an adjuvant treatment between April and June 2010. The proportion of responders (patients with a ≥50% reduction in seizure frequency after rufinamide treatment) was evaluated according to the type of seizure. The proportion of patients who were seizure-free was also evaluated. Adverse events (AEs) were evaluated after 12 weeks of treatment. Results: Among the 15 patients evaluated, one discontinued treatment because of worsening seizures 4 weeks after administration of rufinamide. Seven (46.67%) patients were responders and four patients were seizure-free. There were four responders with convulsive seizures, one each for myoclonic seizures and drop attacks, and spasms. The responder rate was increased to 69.23% by long-term treatment of rufinamide. AEs were experienced by three patients. One patient each experienced somnolence, fatigue, and rash. Conclusion: Rufinamide tablets were efficacious and well tolerated in LGS patients aged 1–4 years, at doses up to 1000 mg per day, when given as add-on therapy to other antiepileptic drugs.

Original languageEnglish
Pages (from-to)897-903
Number of pages7
JournalBrain and Development
Volume40
Issue number10
DOIs
Publication statusPublished - 2018 Nov

Fingerprint

Safety
Seizures
Tablets
Therapeutics
rufinamide
Pediatrics
Spasm
Syncope
Exanthema
Anticonvulsants
Observational Studies
Fatigue
Retrospective Studies

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Developmental Neuroscience
  • Clinical Neurology

Cite this

@article{ae1bf3cb68fb4dc8b36b792cbc2f64ef,
title = "Rufinamide efficacy and safety in children aged 1–4 years with Lennox–Gastaut syndrome",
abstract = "Purpose: The treatment options for Lennox–Gastaut syndrome (LGS), a pediatric epileptic syndrome, are limited, especially in younger children. Rufinamide tablets were safe and effective as an add-on treatment in Korean children and adolescents <20 years of age with LGS. This subgroup analysis aimed to evaluate the efficacy and safety of rufinamide tablets in LGS pediatric patients aged 1–4 years. Methods: This was a retrospective, observational study in LGS patients aged 1–4 years who received 12 weeks of treatment with rufinamide orally as an adjuvant treatment between April and June 2010. The proportion of responders (patients with a ≥50{\%} reduction in seizure frequency after rufinamide treatment) was evaluated according to the type of seizure. The proportion of patients who were seizure-free was also evaluated. Adverse events (AEs) were evaluated after 12 weeks of treatment. Results: Among the 15 patients evaluated, one discontinued treatment because of worsening seizures 4 weeks after administration of rufinamide. Seven (46.67{\%}) patients were responders and four patients were seizure-free. There were four responders with convulsive seizures, one each for myoclonic seizures and drop attacks, and spasms. The responder rate was increased to 69.23{\%} by long-term treatment of rufinamide. AEs were experienced by three patients. One patient each experienced somnolence, fatigue, and rash. Conclusion: Rufinamide tablets were efficacious and well tolerated in LGS patients aged 1–4 years, at doses up to 1000 mg per day, when given as add-on therapy to other antiepileptic drugs.",
author = "Kim, {Shin Hye} and Kang, {Hoon Chul} and Lee, {Joon Soo} and Kim, {Heung Dong}",
year = "2018",
month = "11",
doi = "10.1016/j.braindev.2018.07.020",
language = "English",
volume = "40",
pages = "897--903",
journal = "Brain and Development",
issn = "0387-7604",
publisher = "Elsevier",
number = "10",

}

Rufinamide efficacy and safety in children aged 1–4 years with Lennox–Gastaut syndrome. / Kim, Shin Hye; Kang, Hoon Chul; Lee, Joon Soo; Kim, Heung Dong.

In: Brain and Development, Vol. 40, No. 10, 11.2018, p. 897-903.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Rufinamide efficacy and safety in children aged 1–4 years with Lennox–Gastaut syndrome

AU - Kim, Shin Hye

AU - Kang, Hoon Chul

AU - Lee, Joon Soo

AU - Kim, Heung Dong

PY - 2018/11

Y1 - 2018/11

N2 - Purpose: The treatment options for Lennox–Gastaut syndrome (LGS), a pediatric epileptic syndrome, are limited, especially in younger children. Rufinamide tablets were safe and effective as an add-on treatment in Korean children and adolescents <20 years of age with LGS. This subgroup analysis aimed to evaluate the efficacy and safety of rufinamide tablets in LGS pediatric patients aged 1–4 years. Methods: This was a retrospective, observational study in LGS patients aged 1–4 years who received 12 weeks of treatment with rufinamide orally as an adjuvant treatment between April and June 2010. The proportion of responders (patients with a ≥50% reduction in seizure frequency after rufinamide treatment) was evaluated according to the type of seizure. The proportion of patients who were seizure-free was also evaluated. Adverse events (AEs) were evaluated after 12 weeks of treatment. Results: Among the 15 patients evaluated, one discontinued treatment because of worsening seizures 4 weeks after administration of rufinamide. Seven (46.67%) patients were responders and four patients were seizure-free. There were four responders with convulsive seizures, one each for myoclonic seizures and drop attacks, and spasms. The responder rate was increased to 69.23% by long-term treatment of rufinamide. AEs were experienced by three patients. One patient each experienced somnolence, fatigue, and rash. Conclusion: Rufinamide tablets were efficacious and well tolerated in LGS patients aged 1–4 years, at doses up to 1000 mg per day, when given as add-on therapy to other antiepileptic drugs.

AB - Purpose: The treatment options for Lennox–Gastaut syndrome (LGS), a pediatric epileptic syndrome, are limited, especially in younger children. Rufinamide tablets were safe and effective as an add-on treatment in Korean children and adolescents <20 years of age with LGS. This subgroup analysis aimed to evaluate the efficacy and safety of rufinamide tablets in LGS pediatric patients aged 1–4 years. Methods: This was a retrospective, observational study in LGS patients aged 1–4 years who received 12 weeks of treatment with rufinamide orally as an adjuvant treatment between April and June 2010. The proportion of responders (patients with a ≥50% reduction in seizure frequency after rufinamide treatment) was evaluated according to the type of seizure. The proportion of patients who were seizure-free was also evaluated. Adverse events (AEs) were evaluated after 12 weeks of treatment. Results: Among the 15 patients evaluated, one discontinued treatment because of worsening seizures 4 weeks after administration of rufinamide. Seven (46.67%) patients were responders and four patients were seizure-free. There were four responders with convulsive seizures, one each for myoclonic seizures and drop attacks, and spasms. The responder rate was increased to 69.23% by long-term treatment of rufinamide. AEs were experienced by three patients. One patient each experienced somnolence, fatigue, and rash. Conclusion: Rufinamide tablets were efficacious and well tolerated in LGS patients aged 1–4 years, at doses up to 1000 mg per day, when given as add-on therapy to other antiepileptic drugs.

UR - http://www.scopus.com/inward/record.url?scp=85052306051&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052306051&partnerID=8YFLogxK

U2 - 10.1016/j.braindev.2018.07.020

DO - 10.1016/j.braindev.2018.07.020

M3 - Article

C2 - 30166208

AN - SCOPUS:85052306051

VL - 40

SP - 897

EP - 903

JO - Brain and Development

JF - Brain and Development

SN - 0387-7604

IS - 10

ER -